This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx

• https://x.com/Janetbirdope/status/1858215259355382099/photo/1

Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co Over 5 years: - No difference in relapse btwn standard GC vs. minimal GC + avacopan - Higher DMII rates in standard group Adds to trial + real world data @RheumNow #ACR24 Abst 1598

Alright help me out here; this is pretty implausible, right? Why would be pts be 11% more adherent to UPA? What's the bio-plausibility here? UPA 10% better than other JAKs? Could do a network meta analysis; betting this doens't replicate #ACR24 @RheumNow Abstr#1362 https://t.co/vpPq3vu9Wf

• https://x.com/EBRheum/status/1858196904494186816/photo/1
• https://x.com/EBRheum/status/1858196904494186816/photo/1

#Rheumatoid #arthritis is an independent risk factor for death in nonmetastatic clear cell renal ca ! 👇N=32K, 802 w RA also Caveats immunotherapy Offered = in RA Cancer specific mortality not affected By #RA Frailty & RA affected outcomes #ACR24 @RheumNow @ACRheum #1327 https://t.co/rAQ57BPA19

• https://x.com/Janetbirdope/status/1858197735205188060/photo/1

In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi (28mo vs 17mo) Why? Patient selection, or a real difference between JAKi? Would really like more comparative effectiveness data between JAKi #ACR24 OPAL group ABST1370 @RheumNow https://t.co/OU2ayzqIc8

• https://x.com/drdavidliew/status/1858188438056653021/photo/1

Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF

• https://x.com/EBRheum/status/1858188599910703531/photo/1

Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja

• https://x.com/drdavidliew/status/1858190305398497317/photo/1

Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb

• Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Di…
• https://x.com/RichardPAConway/status/1858183818525753664/photo/1

The idea of patient-initiated follow-up for RA is enticing: patient & physician time is already stretched minimize unnecessary visits/improve access but what actually needs to go into the design, to make it safe/workable? A: plenty. 🇨🇦 pilot underway #ACR24 ABST1041 @RheumNow https://t.co/03u4bhnQ0v

• https://x.com/drdavidliew/status/1858184151306047682/photo/1

STAR trial of GC w/d in RA LDA SEMIRA of GC w/d controlled RA on Toci Very slight disease activity increase, but higher flares No symptomatic adrenal insufficiency, but data of abnormal ACTH stim No good evidence of steroid w/d symptoms Beth Wallace @RheumNow #ACR24 https://t.co/j6UPWlVNIu

• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1